• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Enovis Corporation (Amendment)

    2/13/23 4:16:01 PM ET
    $ENOV
    Industrial Specialties
    Health Care
    Get the next $ENOV alert in real time by email
    SC 13G/A 1 d460522dsc13ga.htm SC 13G/A SC 13G/A

     

     

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    SCHEDULE 13G

    (Rule 13d-102)

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

    TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED

    PURSUANT TO RULE 13d-2.

    Under the Securities Exchange Act of 1934

    (Amendment No. 11)*

     

     

    Enovis Corporation

    (Name of Issuer)

    Common Stock, par value $0.001 per share

    (Title of Class of Securities)

    194014502

    (CUSIP Number)

    December 31, 2022

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☒ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    SCHEDULE 13G

     

      1    

      NAMES OF REPORTING PERSONS

     

      Mitchell P. Rales

      S.S. OR I.R.S. IDENTIFICATION OF ABOVE PERSON

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

      (a)  ☐        (b)  ☐

     

      3  

      SEC USE ONLY

     

      4  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      USA

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5     

      SOLE VOTING POWER

     

      1,798,851

       6   

      SHARED VOTING POWER

     

      -0-

       7   

      SOLE DISPOSITIVE POWER

     

      1,798,851

       8   

      SHARED DISPOSITIVE POWER

     

      -0-

      9    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      1,798,851

    10  

      CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

      ☐

    11  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

      3.3%1

    12  

      TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

      IN

     

    1

    The percentage reported is based on 54,149,679 shares of Common Stock reported as outstanding in Enovis Corporation’s Form 10-Q filed on November 2, 2022.


    Item 1(a)

    Name of Issuer:

    The name of the issuer is Enovis Corporation, a Delaware corporation (the “Issuer”).

     

    Item 1(b)

    Address of Issuer’s Principal Executive Offices:

    The principal executive office of the Issuer is 2711 Centerville Road, Suite 400, Wilmington, Delaware 19808.

     

    Item 2(a)

    Name of Person Filing:

    This Schedule is being filed by Mitchell P. Rales (the “Reporting Person”).

     

    Item 2(b)

    Address of Principal Business Office, or, if None, Residence:

    The principal business address of the Reporting Person is 11790 Glen Road, Potomac, MD 20854.

     

    Item 2(c)

    Citizenship:

    The Reporting Person is a citizen of the United States of America.

     

    Item 2(d)

    Title of Class of Securities:

    This Schedule 13G/A relates to the common stock of the Issuer, par value $0.001 per share (the “Common Stock”).

     

    Item 2(e)

    CUSIP Number:

    The CUSIP Number of the Common Stock is 194014502.

     

    Item 3

    If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

    N/A

     

    Item 4

    Ownership.

    As of December 31, 2022, the total number of shares of Common Stock beneficially owned by the Reporting Person is 1,798,851. 1,752,480 shares of Common Stock are held directly by the Reporting Person, 36,739 shares are held by the Mitchell P. Rales Family Trust, of which the Reporting Person is the trustee, and 9,362 shares are held in trust for his daughters, of which the Reporting Person is the trustee.

     

      (a)

    Amount beneficially owned: 1,798,851

     

      (b)

    Percent of class: 3.3%1

     

      (c)

    Number of shares as to which the person has:

     

      (i)

    Sole power to vote or to direct the vote: 1,798,851

     

      (ii)

    Shared power to vote or to direct the vote: -0-

     

      (iii)

    Sole power to dispose or to direct the disposition of: 1,798,851


      (iv)

    Shared power to dispose or to direct the disposition of: -0-

     

     

    1

    The percentage reported is based on the 54,149,679 shares of Common Stock reported as outstanding in Enovis Corporation’s Form 10-Q filed on November 2, 2022.

     

    Item 5

    Ownership of Five Percent or Less of a Class.

    If this statement is being filed to report the fact that as of the date hereof the Reporting Person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following  ☒.

     

    Item 6

    Ownership of More than Five Percent on Behalf of Another Person.

    N/A

     

    Item 7

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.

    N/A

     

    Item 8

    Identification and Classification of Members of the Group.

    N/A

     

    Item 9

    Notice of Dissolution of Group.

    N/A

     

    Item 10

    Certifications.

    N/A


    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: February 13, 2023
    By:  

    /s/ Mitchell P. Rales

    Name:   Mitchell P. Rales
    Get the next $ENOV alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ENOV

    DatePrice TargetRatingAnalyst
    10/3/2024$62.00Mkt Outperform
    JMP Securities
    6/13/2024$53.00Neutral
    JP Morgan
    2/13/2024$72.00Overweight
    Stephens
    1/22/2024$75.00Buy
    UBS
    1/3/2024Outperform
    William Blair
    12/15/2023$62.00 → $70.00Buy
    Needham
    10/20/2023$75.00Buy
    ROTH MKM
    6/26/2023$70.00Buy
    Needham
    More analyst ratings

    $ENOV
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Enovis Corporation

    SCHEDULE 13G/A - Enovis CORP (0001420800) (Subject)

    8/14/25 9:02:37 AM ET
    $ENOV
    Industrial Specialties
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Enovis Corporation

    SCHEDULE 13G/A - Enovis CORP (0001420800) (Subject)

    8/12/25 12:06:03 PM ET
    $ENOV
    Industrial Specialties
    Health Care

    SEC Form 10-Q filed by Enovis Corporation

    10-Q - Enovis CORP (0001420800) (Filer)

    8/7/25 4:26:39 PM ET
    $ENOV
    Industrial Specialties
    Health Care

    $ENOV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP, Strategy & Business Dev. Pryor Daniel A bought $289,000 worth of shares (10,000 units at $28.90), increasing direct ownership by 7% to 161,115 units (SEC Form 4)

    4 - Enovis CORP (0001420800) (Issuer)

    8/14/25 4:05:08 PM ET
    $ENOV
    Industrial Specialties
    Health Care

    Principal Accounting Officer Kleckner John covered exercise/tax liability with 173 shares, decreasing direct ownership by 2% to 9,834 units (SEC Form 4)

    4 - Enovis CORP (0001420800) (Issuer)

    8/7/25 9:00:04 PM ET
    $ENOV
    Industrial Specialties
    Health Care

    GROUP PRESIDENT, RECON Vogt Louis covered exercise/tax liability with 460 shares, decreasing direct ownership by 1% to 36,385 units (SEC Form 4)

    4 - Enovis CORP (0001420800) (Issuer)

    8/7/25 9:00:06 PM ET
    $ENOV
    Industrial Specialties
    Health Care

    $ENOV
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP, Strategy & Business Dev. Pryor Daniel A bought $289,000 worth of shares (10,000 units at $28.90), increasing direct ownership by 7% to 161,115 units (SEC Form 4)

    4 - Enovis CORP (0001420800) (Issuer)

    8/14/25 4:05:08 PM ET
    $ENOV
    Industrial Specialties
    Health Care

    $ENOV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    JMP Securities initiated coverage on Enovis Corporation with a new price target

    JMP Securities initiated coverage of Enovis Corporation with a rating of Mkt Outperform and set a new price target of $62.00

    10/3/24 7:29:21 AM ET
    $ENOV
    Industrial Specialties
    Health Care

    JP Morgan initiated coverage on Enovis Corporation with a new price target

    JP Morgan initiated coverage of Enovis Corporation with a rating of Neutral and set a new price target of $53.00

    6/13/24 7:06:52 AM ET
    $ENOV
    Industrial Specialties
    Health Care

    Stephens initiated coverage on Enovis Corporation with a new price target

    Stephens initiated coverage of Enovis Corporation with a rating of Overweight and set a new price target of $72.00

    2/13/24 6:34:49 AM ET
    $ENOV
    Industrial Specialties
    Health Care

    $ENOV
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Enovis to Participate in Upcoming Investor Conferences

    Wilmington, DE, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE:ENOV), an innovation-driven, medical technology growth company, today announced that its management team will participate in the following investor conferences: Canaccord Genuity 45th Annual Growth Conference on Wednesday, August 13th at 8:30 a.m. Eastern Time.Wells Fargo Healthcare Conference on Wednesday, September 3rd at 2:15 p.m. Eastern Time.Baird 2025 Global Healthcare Conference on Wednesday, September 10th at 3:10 p.m. Eastern Time. A link to the live audio webcasts, as well as a replay of these events, will be available on the Company's website under the Investors tab at Events and Presentations. ABOUT

    8/8/25 9:00:00 AM ET
    $ENOV
    Industrial Specialties
    Health Care

    Enovis Announces Second Quarter 2025 Results

    Continued commercial momentum with second-quarter sales growth of 7% on a reported basisSecond-quarter Reconstructive sales grew 11% year-over-year on a reported basis  Wilmington, DE, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation ("Enovis" or "the Company") (NYSE:ENOV), an innovation-driven medical technology growth company, today announced its financial results for the second quarter ended July 4, 2025. The Company will host an investor conference call and live webcast to discuss these results today at 8:30 am ET. Second Quarter 2025 Financial Results Enovis' second-quarter net sales of $565 million grew 7% on a reported basis and 5% on an organic basis from the same quarter

    8/7/25 6:00:00 AM ET
    $ENOV
    Industrial Specialties
    Health Care

    Enovis to Host Second Quarter 2025 Results Conference Call on August 7th

    Wilmington, DE, July 08, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE:ENOV), an innovation-driven, medical technology growth company, announced that it will host an investor conference call and live webcast to discuss its second quarter 2025 financial results on Thursday, August 7th, 2025, at 8:30 a.m. Eastern Time and issue an earnings press release earlier that morning. A presentation related to the call, as well as a webcast, can be accessed from the "Investors" section of Enovis' website at www.enovis.com. Conference Call/Webcast Information Investors can access the live webcast via a link on the Enovis website. For those planning to participate on the call, please dial (833) 6

    7/8/25 4:05:00 PM ET
    $ENOV
    Industrial Specialties
    Health Care

    $ENOV
    Leadership Updates

    Live Leadership Updates

    View All

    Enovis Announces Appointment of Damien McDonald as Chief Executive Officer

    Damien McDonald appointed CEO, effective as of May 12, 2025Company reiterates guidance for first quarter revenues and aEBITDA WIlmington. DE, April 02, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation ("Enovis" or "The Company") (NYSE:ENOV), a leader in medical technology innovation, today announced the appointment of Damien McDonald as Chief Executive Officer, effective May 12, 2025. Mr. McDonald will also join the Enovis Board of Directors following the conclusion of the Company's 2025 Annual Meeting of Stockholders on May 21, 2025. He will succeed Matt Trerotola, who previously announced his intention to retire as CEO and has informed the Board that he will not stand for re-election at th

    4/2/25 6:30:00 AM ET
    $ENOV
    Industrial Specialties
    Health Care

    Maplebear Set to Join S&P MidCap 400; Enovis to Join S&P SmallCap 600

    NEW YORK, Jan. 7, 2025 /PRNewswire/ -- Maplebear Inc. (NASD: CART) will replace Enovis Corp. (NYSE:ENOV) in the S&P MidCap 400, and Enovis will replace Arch Resources Inc. (NYSE:ARCH) in the S&P SmallCap 600 effective prior to the opening of trading on Tuesday, January 14. S&P SmallCap 600 constituent CONSOL Energy Inc. (NYSE:CEIX) is acquiring Arch Resources in a deal expected to be completed soon, pending final closing conditions. Following completion of the merger, CONSOL Energy will be renamed Core Natural Resources Inc., and its ticker will change to CNR. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index

    1/7/25 6:19:00 PM ET
    $ARCH
    $CART
    $CEIX
    Coal Mining
    Energy
    Real Estate
    Industrial Specialties

    Enovis Appoints Tim Czartoski as President, U.S. Surgical and Global Product and Enabling Technologies

    WILMINGTON, DE, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Enovis™ (NYSE:ENOV), an innovation-driven medical technology growth company, is pleased to announce the appointment of Tim Czartoski to the position of President, U.S. Surgical and Global Product and Enabling Technologies. Mr. Czartoski has direct responsibility for the Company's U.S. Surgical business, including the global surgical product engine and enabling technologies. He reports to Louie Vogt, Group President of Enovis' Reconstructive (Recon) Business Group. Mr. Czartoski is a successful MedTech executive with over 22 years of experience at Depuy Synthes, the Orthopaedics Company of Johnson & Johnson, where he progressed in le

    9/9/24 3:50:00 PM ET
    $ENOV
    Industrial Specialties
    Health Care

    $ENOV
    Financials

    Live finance-specific insights

    View All

    Enovis Announces Second Quarter 2025 Results

    Continued commercial momentum with second-quarter sales growth of 7% on a reported basisSecond-quarter Reconstructive sales grew 11% year-over-year on a reported basis  Wilmington, DE, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation ("Enovis" or "the Company") (NYSE:ENOV), an innovation-driven medical technology growth company, today announced its financial results for the second quarter ended July 4, 2025. The Company will host an investor conference call and live webcast to discuss these results today at 8:30 am ET. Second Quarter 2025 Financial Results Enovis' second-quarter net sales of $565 million grew 7% on a reported basis and 5% on an organic basis from the same quarter

    8/7/25 6:00:00 AM ET
    $ENOV
    Industrial Specialties
    Health Care

    Enovis to Host Second Quarter 2025 Results Conference Call on August 7th

    Wilmington, DE, July 08, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE:ENOV), an innovation-driven, medical technology growth company, announced that it will host an investor conference call and live webcast to discuss its second quarter 2025 financial results on Thursday, August 7th, 2025, at 8:30 a.m. Eastern Time and issue an earnings press release earlier that morning. A presentation related to the call, as well as a webcast, can be accessed from the "Investors" section of Enovis' website at www.enovis.com. Conference Call/Webcast Information Investors can access the live webcast via a link on the Enovis website. For those planning to participate on the call, please dial (833) 6

    7/8/25 4:05:00 PM ET
    $ENOV
    Industrial Specialties
    Health Care

    Enovis Announces First Quarter 2025 Results

    Continued commercial momentum with first-quarter sales growth of 8% on a reported basis and strong adjusted EBITDA margin expansion First-quarter Reconstructive sales grew 11% year-over-year on a reported basis Appointed Damien McDonald as CEO, effective May 12th, 2025 Wilmington, DE, May 08, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation ("Enovis" or "the Company") (NYSE:ENOV), an innovation-driven medical technology growth company, today announced its financial results for the first quarter ended April 4, 2025. The Company will host an investor conference call and live webcast to discuss these results today at 8:30 am ET. First Quarter 2025 Financial Results Enovis' first-quarte

    5/8/25 6:00:00 AM ET
    $ENOV
    Industrial Specialties
    Health Care

    $ENOV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Enovis Corporation

    SC 13G/A - Enovis CORP (0001420800) (Subject)

    11/14/24 1:28:31 PM ET
    $ENOV
    Industrial Specialties
    Health Care

    SEC Form SC 13G/A filed by Enovis Corporation (Amendment)

    SC 13G/A - Enovis CORP (0001420800) (Subject)

    4/5/24 12:21:51 PM ET
    $ENOV
    Industrial Specialties
    Health Care

    SEC Form SC 13G/A filed by Enovis Corporation (Amendment)

    SC 13G/A - Enovis CORP (0001420800) (Subject)

    2/14/24 10:04:36 AM ET
    $ENOV
    Industrial Specialties
    Health Care